Neoplasm malignant

14 trials 7 recruiting MedDRA PT
14 Registered trials
7 Recruiting
12 Unique sponsors
15 Unique IMPs
14 Commercial trials
Drug classes (ATC)
— ATC code not specified 13
L Oncology (ATC L) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Kinase inhibitor 3 substances
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
RAF/BRAF inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase II/III: 1 Phase II: 2 Phase I/II: 1 Phase I: 10 Phase I (Other): 1

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase II/III

1 trial
  • Taiho Oncology Inc. Commercial
    FUTIBATINIB
    2024-512217-40-00 4 countries 2024 n=5
    Recruiting

Phase II

2 trials
  • Merck Sharp & Dohme LLC Commercial
    MK-1084
    2025-521737-91-00 9 countries 2025 n=74
    Recruiting
  • Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial
    SKB264
    2023-508700-38-00 2 countries n=31
    Ended

Phase I/II

1 trial
  • Pentixapharm AG Commercial
    GALLIUM (68GA), PENTIXAFOR; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; PENTIXATHER, YTTRIUM-90
    2024-512097-98-00 1 country 2023 n=15
    Recruiting

Phase I

10 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2023-505006-41-00 1 country 2015 n=100
    Ended
  • AstraZeneca AB Commercial
    IMP not specified
    2023-509605-77-00 5 countries 2019 n=205
    Ended
  • Chugai Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2023-508764-30-00 3 countries 2024 n=30
    Ended
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2024-517984-21-00 3 countries n=19
    Ended
  • Genmab A/S Commercial
    IMP not specified
    2025-523931-21-00 1 country 2026 n=77
    Recruiting
  • Gilead Sciences Inc. Commercial
    IMP not specified
    2025-522397-36-00 1 country 2025 n=35
    Recruiting
  • Incyte Corp. Commercial
    IMP not specified
    2022-501505-13-00 4 countries 2023 n=140
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-516006-32-00 2 countries 2025 n=30
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-515351-37-00 1 country 2023 n=40
    Recruiting
  • Daiichi Sankyo Inc. Academic
    IMP not specified
    2024-517984-21-00 3 countries n=19
    Ended

Phase I (Other)

1 trial
  • Novartis Pharma AG Commercial
    3-[6-(1-BENZYLPIPERIDIN-4-YL)-3-OXO-1H-ISOINDOL-2-YL]PIPERIDINE-2,6-DIONE; CAPMATINIB; HETERODIMERIC INTERLEUKIN-15; IERAMILIMAB; LACNOTUZUMAB; NAPORAFENIB; SPARTALIZUMAB; TAMINADENANT; TRAMETINIB DIMETHYL SULFOXIDE
    2023-508841-42-00 8 countries 2019 n=75 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 2 Phase I 0
Daiichi Sankyo Inc. Commercial 2 Phase I 0
Merck Sharp & Dohme LLC Commercial 2 Phase I, Phase II 2
Chugai Pharmaceutical Co. Ltd. Commercial 1 Phase I 0
Genmab A/S Commercial 1 Phase I 1
Gilead Sciences Inc. Commercial 1 Phase I 1
Incyte Corp. Commercial 1 Phase I 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase I 1
Taiho Oncology Inc. Commercial 1 Phase II/III 1
Novartis Pharma AG Commercial 1 Phase I (Other) 0
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial 1 Phase II 0
Pentixapharm AG Commercial 1 Phase I/II 1
New trials by year
2019
2
2023
3
2024
2
2025
3
2026
1
← All indication landscapes